proteins. 8 Studies have shown that LncRNA can regulate gene expression in epigenetics, transcriptional grade and post-transcriptional grade and the regulating ways include chromosome modification, transcriptional activation and interference, etc. 9 There is a close correlation between LncRNA and tumourigenesis as well as tumour development. 10 Some LncRNAs show significant differences in expression between normal tissues and tumour tissues and abnormal LncRNA may play an important role in tumourigenesis. 11 There is evidence to predict that LncRNA may become a new marker of tumour diagnosis and judgement, prognosis and therapeutic efficacy as well as a new target for tumour gene therapy. 12 FER1L4, one of the important members of LncRNA, is closely related to tumourigenesis and tumour development. 13 In recent years, several studies have confirmed that FER1L4 expression is closely related to colon cancer and gastric cancer. 14, 15 The previous experimental study of our research group has preliminarily verified that FER1L4 is significantly higher in glioma cells than in astroglial cell lines and that FER1L4 is also closely related to proliferation, invasion and apoptosis of glioma cell lines. 16 However, its expression in patients with glioma at different grades, its correlation with important clinical pathological factors and prognosis of patients with gliomas and the specific molecular mechanisms that LncRNA FER1L4 plays biological functions in glioma cells need further experiments to confirm currently.
In this study, it was found that the expression of LncRNA FER1L4
was significantly up-regulated in high-grade glioma patients compared with low-grade expression. The knockdown of FER1L4 expression could significantly inhibit glioma cell proliferation and cell cycle. In vivo experiments confirmed that the down-regulation of FER1L4 inhibited tumour growth in vivo. In addition, it is also found that FER1L4 can be used as competitive endogenous RNA (ceRNA)
to adsorb E2F1 and thereby up-regulate E2F1, thus promoting the cycle and proliferation of glioma cells. It may be one of the molecular mechanisms that FER1L4 plays its oncogene-like role in gliomas. 
| MATERIAL S AND ME THODS

| Human tissue specimens
| Cell culture
The gliomas S373-MG, U251, U87-MG, SHG-44 and normal astrocytes 1800 derived from the Cell Library of the Chinese Academy of Sciences (PRC) were all respectively cultured in medium containing 10% fetal bovine serum, DMEM (Gibco BRL, USA) medium containing 1% penicillin (Gibco) and medium containing 5% CO 2 at 37°C.
Passaging and related operations were conducted after the degree of cell fusion reached 80%.
| Cell transfection
The primers of FER1L4 were synthesized by Shanghai Invitrogen Biotechnology Co., Ltd. 
| Real-time quantitative PCR
Total RNA was extracted using Trizol and it was quantitated using UV spectrophotometer. RNA was reversely transcribed into cDNA and amplified using RT-PCR according to the instructions given inthe reverse transcription kit (Fermentas, USA 
| CCK-8 cell proliferation assay
Cells in the logarithmic growth phase were seeded in 96-well plates, with 5000 cells per well and three replicates were set in each group.
Twenty four, 48, 72 and 96 hours after transfection, 10 μL of CCK-8 (10 μL, C0038; Beyotime Institute) solution was added to each well and incubated in the incubator for 2 hours. The absorbance of each well was determined with the enzyme-linked immunosorbent detector at 450 nm and the growth of the cells was compared.
| Cell cycle analysis
The cells in logarithmic growth phase were seeded and cultured in six-well plates. Drug solution was added after the cells grew to 70%. After culturing for a period of time, they were digested with appropriate amounts of trypsin to prepare a single cell suspension, centrifuged at 150 g, washed twice with PBS and fixed with 75%
cold ethanol at −20°C. Before machine determination, they were centrifuged to remove the ethanol, washed twice with PBS, filtered through 300 mesh nylon mesh and prepared to be cell suspension with 200 μL PBS suspension cells. 300 μL of PI dye solution was added and they were dyed in a dark environment at 4°C for more than 30 minutes; 10 000 cells were counted using the FACSCalibur, BD, USA and the proportion of each phase (G0/G1, G2/M, S) was finally statistically analysed.
| Western blot analysis
The cells in logarithmic growth phase were lysed and the super- and scanning the images with a gel image analyser, the ratio of the expression level of specific protein (strand gray scale) and that of internal reference (β-actin) in each group was determined with the four-star image processing system to take it as a parameter for their expression levels. The tumours were detached to measure their sizes, weigh them and record and photograph.
| Xenograft model
| Luciferase assays
Glioma cells (4 × 10 4 ) were seeded in triplicate in 96-well plates and allowed to settle for 24 hours. MiR-327 mimics, pGL3-FER1L4-wild and pGL3-FER1L4-mut vectors were purchased from RiboBio (RiboBio Co. Ltd, Guangzhou, Guangdong) and were respectively cotransfected with U251 and U373MG cells as experimental groups and the group with only transfected vector cells was taken as the control group. The transfection efficiency was tested to determine successful transfection. The luciferase assay was performed by using the dual-luciferase reporter assay system (Promega) 48 hours after transfection. Three independent experiments were performed and the data are presented as the mean ± SD.
| Statistical analysis
The relationship between the gene expression and clinical characteristics of patients was analysed using chi-squared test and rank correlation analysis and the prognosis was analysed using K-M survival analysis. The in vitro cell experiments were repeated for three times and the data were expressed as the mean ± SD. The t test was performed to compare the mean of the two groups. The two-sample t test was applied to compare the means of the two groups. The ANOVA test was used to compare the means of the three groups.
P < 0.05 was considered statistically significant. Statistical analysis was conducted using SPSS17.0 and graphpad prism 5 statistical software. 
| RE SULTS
| The change in FER1L4 expression has effect on the expression of E2F1, downstream genes ERK, P21 and cyclinD2
The study above showed that the expression of FER1L4 and E2F1 in different grades of glioma tissues showed a significant positive correlation. The results suggest that there may be some regulatory relationship between FER1L4 and E2F1. Therefore, E2F1
F I G U R E 2 The LncRNAs FER1L4 and E2F1 expression in different grades of gliomas (WHO I-IV) from TCGA database. A and B, Expression of FER1L4 (A) and E2F1 (B) level in different grades of gliomas (low grade: WHO I-II gliomas; high grade: WHO III-IV gliomas)
(***P < 0.001). C and D, Kaplan-Meier post-operative survival curve for patterns of patients with glioma and FER1L4 and E2F1 expression (***P < 0.001). E, The linear correlations between the expression level of FER1L4 and E2F1 in glioma tissues from TCGA database (R = 0.325, P < 0.001). The data were obtained using the logistic regression analysis.
expression was determined by using Western blot when the expression of FER1L4 was down-regulated by SiRNA, which showed that the protein expression of E2F1 was significantly down-regulated ( Figure 5A 
| FER1L4 regulates glioma cell proliferation by ceRNA mechanism
The miRNAs that constitute ceRNA pattern with FER1L4 and E2F1
were searched from lnceDB database. The Reference Sequence of FER1L4 as well as E2F1 was obtained from GenBank and that of miRNA was obtained from miRbase. Possible bindings between FER1L4, E2F1 and miRNA were respectively predicted based on Miranda and the miRNAs likely to bind both FER1L4 and E2F1 included: hsa-miR-4262, hsa-miR-346, hsa-miR-93, hsa-miR-326, hsamiR-181, hsa-miR-520,hsa-miR-367, hsa-miR-4644, hsa-miR-329, hsa-miR-874, hsa-miR-372, hsa-miR-485, hsa-miR-4306 and hsamiR-302, with a total of 14 miRNAs. FER1L4 was interfered by siRNA and the PCR results showed that hsa-miR-372 expression was significantly up-regulated (P < 0.01) ( Figure 6A ). The fluorescein-labelled test further confirmed the direct interaction between FER1L4 and hsa-miR-372 (Figure 6B-D) . In addition, studies have shown that in breast cancer cells, hsa-miR-372 has been identified to inhibit tumour proliferation through direct regulation on E2F1. 17 Therefore, it is speculated that FER1L4/hsa-miR-372/E2F1 may serve as a regulatory mechanism of ceRNA for glioma cell proliferation. Further overexpression of hsa-miR-372 indicated the down-regulation of both FER1L4 and E2F1 expression ( Figure 6E and F) . The results further proved that as a ceRNA, FER1L4/hsa-miR-372/E2F1 regulates the molecular mechanism of glioma cell proliferation.
| DISCUSS IONS
Glioma is a highly malignant primary nervous system tumour. 2 The prognosis of most patients is still very poor in spite of the active surgical treatment and adjuvant therapy. 18 Particularly, the average survival time of glioblastoma is still not more than 2 years. 19 Current studies show that the occurrence and development of gliomas are closely related to the abnormal expression of various oncogenes and tumour suppressor genes. 20 However, the precise molecular mechanism for its development is not very clear. Therefore, it is of great significance to further explore the relationship between the changes in new gene function and the development and malignant characteristics of glioma tumours, to reveal the precise molecular mechanism of its occurrence and development, to develop reasonable therapeutic drugs and determine the prognosis and to further improve the treatment of glioma and the prognosis of glioma patients. 3 The ceRNA hypothesis has been paid attention to by academic community after being proposed, as it represents a brand new mode of post-transcriptional gene expression regulation. 21 A number of studies have shown that lncRNAs can participate in the regulation of various biological processes through ceRNA mechanism, such as muscle differentiation, cell resistance, neural cell differentiation, etc. 22 In addition, lncRNA, as ceRNA, plays an important role in carcinogenesis. 23 For example, in ovarian cancer, lncRNA HOST2 upregulates the expression of HMGA2 and c-MYC by the competitive binding with let-7b-5p, thereby promoting the occurrence and development of ovarian cancer.
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FER1L4, as a newly discovered LncRNA, is mainly focused on gastric cancer and colon cancer in current studies. 13, 14 In the study The previous experimental study of this subject has preliminarily confirmed that FER1L4 is significantly higher in glioma cells than in astrocytes cell lines. FER1L4 can significantly promote the proliferation, invasion and apoptosis of glioma cell lines. 16 Our study is inconsistent with the results of studies on gastric cancer and colon cancer indicating that FER1L4 may play an inconsistent role in different tumour cells. 16 In this study, it is found that FER1L4
was highly expressed in high-grade gliomas in different grades of glioma tissues and its high expression was significantly negatively correlated with the prognosis of glioma patients. The knockdown of FER1L4 expression significantly inhibited the proliferation of glioma cells, proving that FER1L4 plays an oncogene role in glioma cells.
The transcription factor E2F family consists of eight different family members, from E2F1 to E2F8. 26 E2F1 was screened by Helin in 1992. It can be used as a transcription factor to regulate the cell cycle, but high expression of E2F1 can also induce many types of
The lncRNA FER1L4 regulates target gene expression through E2F1. A and B, Western blot of the RNA level of E2F1 in glioma cells (U251 and U373MG) transfected with FER1L4-siRNA or control siRNA (**P < 0.01). C-E, Western blot analysis of the expression level of target genes (p21, cyclin D2, P-ERK) in glioma cells (U251 and U373MG) transfected with FER1L4-siRNA or control siRNA (*P < 0.05, **P < 0.01) apoptosis. 27 Therefore, E2F1 possesses double properties of carcinogenesis and apoptosis induction and its specific effects are related to the specificity of organ tissues and so on. 28 In some tumours such as lung cancer and breast cancer, E2F1 promotes canceration. 29, 30 Our study found that high expression of E2F1 appears in glioma tissues and it gradually increases with the rise in glioma WHO grade.
Similarly, high expression of E2F1 predicts a poor prognosis of gliomas. There was a significant positive correlation between its expression in gliomas and FER1L4 expression suggesting a synergistic effect between FER1L4 and E2F1, which participate in the malignant biological process of glioma. Subsequently, by down-regulating FER1L4, we confirmed that E2F1 expression was also down-regulated and that FER1L4 and E2F1 were involved in the cell cycle of gliomas (FER1L4 regulates the cell progression in G2-M by regulating E2F1).
Further experiments confirmed that FER1L4 can directly bind with miR-372 and the down-regulation on FER1L4 expression can significantly up-regulate E2F1 expression and down-regulate miR-372 expression. Furthermore, in the previous literature in breast cancer cells, it has been clarified that hsa-miR-372 can inhibit tumour proliferation through direct regulation on E2F1. 17 Therefore, it is speculated that FER1L4/miR-372/E2F1 may serve as a ceRNA regulatory mechanism for glioma cell proliferation. Further overexpression of miR-372 showed that the expression of FER1L4 and E2F1 was down-regulated and the results further confirmed that as a ceRNA, FER1L4/miR-372/E2F1 regulates the molecular mechanism of glioma cell proliferation.
| CON CLUS IONS
In summary, there is evidence to speculate that Long Non-Coding 
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